Instruction for use: Interferon alfa

Trade name of the drug – Alfaferone, Wellferon, Interferon alfa-2 human recombinant, Interferon leukocytic human, Interferon leukocytic human fluid, Interferon leukocytic human siccum, Interferon leukocytic human, Interferon human leucocytic in suppositoriums, Interferon leucocytic human concentrated fluid, Interferon alfa-2 ointment, Inferon, Locferon

The Latin name of the substance Interferon alfa

Interferonum alpha (genus. Interferoni alpha)

Pharmacological groups:

Interferons

Antiviral drugs (excluding HIV)

Nosological classification (ICD-10)

A63.0 Anogenital (venereal) warts: Anogenital warts; Venereal warts; Condylomata genital; Condyloma pointed; Externally pointed genital warts; Externally pointed condyloma; Pointed Condyloma; Flat condyloma

A84 Tick-borne viral encephalitis: Tick-borne encephalitis; Tick-borne encephalitis

B16 Acute hepatitis B: Viral hepatitis B; Hepatitis B; Acute hepatitis; Vaccination against hepatitis B; Subacute hepatitis; Acute viral hepatitis B; Acute lingering hepatitis B

B17.1 Acute hepatitis C: Viral active hepatitis C; Viral hepatitis C; Hepatitis C

B20-B24 Disease caused by human immunodeficiency virus [HIV]: Deployed stage of HIV infection; AIDS in children; HIV / AIDS infection; Infections with HIV; AIDS; Human Immunodeficiency Virus HIV-1; HIV-1 infection HIV infection; HIV

B21.0 HIV disease, with manifestations of Kaposi's sarcoma: Kaposi angioreticulosis; Endotheliosarcoma; Kaposi angiosarcomatosis; Kaposi hemangiosarcoma; Kaposi hemorrhagic sarcoma; Kaposi multiple hemorrhagic sarcoma; Kaposi telangiectatic pseudo-sarcoma; Kaposi's Sarcoma in AIDS; Kaposi's sarcoma on AIDS; Kaposi's sarcoma on the background of AIDS

B37 Candidiasis: Visceral candidiasis; Invasive Candidiasis; Candidiasis of the larynx; Candidiasis of the digestive tract; Candidiasis of the skin and mucous membranes; Candidiasis of mucous membranes and skin; Candidiasis of the mucous membranes; Candidiasis due to Candida albicans; Candidomycosis; Acute pseudomembranous candidiasis; Chronic forms of candidiasis

B37.2 Skin and Nail Candidiasis: Fungal paronychia; Fungal Eczema; Fungal dermatosis; Fungal diseases of smooth skin; Fungal lesions of smooth skin; Fungal lesions of smooth body skin; Fungal nail infections; Yeast Infection of the Skin; Candidiasis of the skin; Candidiasis of skin and mucous membranes of mouth and mouth; Candidiasis of the skin of nail rollers; Candidiasis of nail rollers; Candidiasis of nails; Candidiasis with lesions of the skin and mucous membranes; Candidiasis of mucous membranes and skin; Candida paronychia; Candidomycosis of the skin; Cutaneous candidal infections; Cutaneous candidiasis; Interdigital fungal erosion; Mycotic dermatitis; Paronychia candida; Superficial form of skin candidiasis; Superficial candidiasis; Superficial candidiasis of nails; Superficial mycosis of the skin; Chronic candidiasis of the skin

C20 Malignant neoplasm of rectum: Common colorectal cancer; Common colon cancer; Rectal cancer of the rectum; Disseminated colorectal cancer; Malignant tumor of colon and rectum; Colorectal carcinoma; Colorectal cancer; Locally spread rectal cancer; Metastatic Colorectal Cancer; Colorectal cancer; Rectal cancer

C43 Malignant melanoma of skin: Malignant melanoma; Localized malignant melanoma; Localized form of malignant melanoma; Melanoma; Melanoma after surgical resection; Metastatic melanoma; Common metastatic malignant melanoma; Metastasizing form of malignant melanoma; Disseminated malignant melanoma

C44 Other malignant neoplasms of the skin: Malignant skin tumors; Basalioma; Basaliomas; Basal cell epithelioma; Basal cell carcinoma; Basal cell carcinoma of the skin; Basal cell carcinoma of the skin; Malignant reticulosis; Ulcerated basal cell; Skin Cancer; Skin carcinoid; Skin Lymphoma; Primary reticulosis; Primary skin reticulosis; Squamous cell carcinoma; Squamous cell carcinoma of the skin; Superficial skin tumors; Skin cancer; Reticulosis of the skin; Skin Reticulosarcoma; Sarcomatosis of the skin; Skin cancer (endophytic forms of I and II stages); Squamous cell carcinoma and basal cell carcinoma

C57.9 Malignant neoplasm of female genital organs, unspecified

C64 Malignant neoplasm of kidney, other than renal pelvis: Wilms tumor; Kidney Cancer; Metastatic Renal Cell Carcinoma; Renal carcinoma; Inoperable kidney carcinomas; Metastatic kidney carcinoma; Metastatic Renal Cell Carcinoma; Wilms tumor; Wilms swelling; Adenomyosarcoma; Adenomyocystosarcoma; Adenosarcoma of the kidney; Kidney Cancer; Common renal cell carcinoma; Nephroblastoma; Nephroma; Embryonal nephroma; Recurrent carcinoma of the kidney; Birch-Hirschfeld Tumor; Common renal cell carcinoma; Tumors of the kidney

C83 Diffuse non-Hodgkin's lymphoma: Diffuse B-large-cell non-Hodgkin's lymphoma; Malignant lymphoma; Malignant lymphoma, especially of the histiocytic type; Lymphoblastic non-Hodgkin's lymphoma; Lymphoma non-Hodgkin's diffuse; Hepatic Lymphoma; Recurrence of lymphoma; Recurrent non-Hodgkin's lymphoma; Lymphoma of the liver

C84.0 Mushroom mycosis: Mycosis mushroom; Fungoid granuloma

C91.4 Hairy-cell leucosis

C92.1 Chronic myeloid leukemia: Myeloleukemia chronic; Myeloid leukemia chronic Ph-negative; Exacerbation of chronic myelogenous leukemia; The subleukemic form of chronic myelogenous leukemia; Chronic leukemia myeloid leukemia; Chronic myeloblastic leukemia; Chronic myelogenous leukemia; Chronic myelomonocytic leukemia; Idiopathic hypereosinophilic syndrome

D84.9 Unspecified Immunodeficiency: Pneumonia in immunodeficient states; Autoimmune disease; Autoimmune diseases; Severe immunodeficiency; immune deficiency; Immunodeficiency; immunodeficiency diseases; Immunodeficiency states due to surgery; Immunotherapy for cancer; Immunomodulation; Infections in patients with weakened immune systems; Correction of immune deficiency; Correction of immunodeficiencies; Correction of a weakened immune system; Correction of a weakened immunity in immunodeficient states; Violation of immunity; Violation of the immune status; Immune System Disorders; Primary immunodeficiency; Maintaining immunity; Lowering the body's defenses; Lowering the immunity; Lowering the immunity of colds and infectious diseases; The decrease of the immune status; Lowered resistance to infections; Lowered resistance to infections and colds; Lowered resistance; Immunosuppression; Predisposition to colds; acquired immune deficiencies; Radiation immunodeficiency; The development of immunodeficiency; Immune dysfunction syndrome; immunodeficiency syndrome; primary immunodeficiency syndrome; Reducing the body's defenses; Immunosuppression; Reduced immune defense; Reducing local immunity; Reducing the total body resistance; The decrease in cell-mediated immunity; Reduced resistance to infections in children; Reducing the body's resistance; Reduced resistance; reduced immunity; Status immunodeficiency; Stimulation of the processes of nonspecific immunity; Heavy selective secondary immunodeficiency; immunity Oppression; Primary immunodeficiency

G35 Multiple Sclerosis: Disseminated Sclerosis; Multiple sclerosis; Recurrent multiple sclerosis; Secondary-progressive multiple sclerosis; Exacerbation of multiple sclerosis; Mixed forms of multiple sclerosis

K73 Chronic hepatitis, not elsewhere classified: Inflammatory liver disease; Hepatitis autoimmune; Hepatitis chronic; Infection of the liver; Chronic hepatitis with signs of cholestasis; Chronic reactive hepatitis; Chronic persistent hepatitis; Chronic infectious hepatitis; Chronic active hepatitis; Chronic inflammatory liver disease; Autoimmune Hepatitis; Chronic hepatitis is aggressive

N71 Inflammatory diseases of the uterus other than the cervix: Intrauterine infections; Inflammatory diseases of female genitalia; Inflammatory diseases of female genital organs; Infection of the genitals; Chronic endometriometritis; Chronic inflammatory disease of the uterus; Endometritis; Endometriometry

N80 Endometriosis: Endometrioid endometriosis

Z29.1 Prophylactic immunotherapy: Vaccination against viral infections; donor Vaccination; Vaccination and revaccination; Vaccination of newborns; Vaccination against hepatitis B; Immunization; Correction of the immune status; Therapeutic and prophylactic immunization; Preventive immunization; Specific immunoprophylaxis; Stimulation of the processes of nonspecific immunit

Z54 recovery period: The recovery period; The recovery period after illness; Recovery; The recovery from the flu and colds; Recovery after illness; The lack of mineral salts in the period of convalescence; The period of recovery after illness; The period of recovery after illness and surgery; The period of recovery after a serious illness; The period of convalescence after illness; rehabilitation period; rekovalestsentsii period after infectious diseases; decubation; The period of convalescence after surgery and infectious diseases; The period of convalescence after prolonged infections; The period of convalescence after serious diseases; The period of convalescence after severe infections; Rehabilitation period; convalescent state; Convalescence after illness; Convalescence after infectious diseases; Convalescence after debilitating diseases; Convalescence after infectious diseases; Convalescence at an elevated blood loss; Status of convalescence after illness

Pharmacology

Pharmacological action - antiviral, immunomodulating, antitumor, antiproliferative.

Prevents viral infection of cells, changes the properties of the cell membrane, prevents adhesion and penetration of the virus into the cell. It initiates the synthesis of a number of specific enzymes, disrupts the synthesis of viral RNA and proteins of the virus in the cell. It changes the cytoskeleton of the cell membrane, metabolism, preventing the proliferation of tumor cells (especially). It modulates the synthesis of some oncogenes, which leads to normalization of neoplastic transformation of cells and inhibition of tumor growth. Stimulates the process of antigen presentation to immunocompetent cells, modulates the activity of killers participating in antiviral immunity. With the / m introduction, the rate of absorption from the site of administration is uneven. The time to reach Cmax in plasma is 4-8 hours. In the systemic circulation 70% of the administered dose is distributed. T1 / 2 - 4-12 hours (depends on the variability of absorption). It is excreted mainly by the kidneys by glomerular filtration.

Application of substance Interferon alfa

Hairy cell leukemia, chronic myelogenous leukemia, viral hepatitis B, viral active hepatitis C, primary (essential) and secondary thrombocytosis, a transitional form of chronic granulocyte leukemia and myelofibrosis, multiple myeloma, kidney cancer; AIDS related Kaposi's sarcoma, mushroom mycosis, reticulosarcoma, multiple sclerosis, prevention and treatment of influenza and acute respiratory viral infection.

Contraindications

Hypersensitivity, severe heart disease (including in the history), acute myocardial infarction, expressed violations of the liver, kidney or hematopoiesis system, epilepsy and / or other disorders of the central nervous system; Chronic hepatitis against decompensated hepatic cirrhosis; Chronic hepatitis in patients receiving or shortly before receiving immunosuppressant therapy (except for short-term pre-treatment with steroids).

Restrictions

Pregnancy, breast-feeding (should stop breastfeeding), children's age.

Side effects of the substance Interferon alfa

Lethargy, fever, chills, loss of appetite, muscle pain, headache, joint pain, sweating, nausea, vomiting, taste changes, dry mouth, weight loss, diarrhea, abdominal pain, constipation, flatulence, increased peristalsis, Heartburn, liver dysfunction, hepatitis, dizziness, vision disorders, ischemic retinopathy, depression, drowsiness, impaired consciousness, nervousness, sleep disturbance, skin allergic reactions (rash, itching).

Interaction

It disrupts the metabolism of cimetidine, phenytoin, warfarin, theophylline, diazepam, propranolol.

Routes of administration

IM, SC, intranasal.

Precautions for the substance Interferon alfa

It is necessary to avoid combinations with drugs acting on the central nervous system, immunosuppressive drugs. Throughout the course it is necessary to control the content of blood elements and the function of the liver. To mitigate side effects (influenza-like symptoms), simultaneous administration of paracetamol is recommended.